Arcus Capital Partners LLC Takes $321,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Arcus Capital Partners LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, HoldingsChannel.com reports. The firm bought 965 shares of the company’s stock, valued at approximately $321,000.

Several other hedge funds have also modified their holdings of the stock. R Squared Ltd acquired a new stake in Medpace in the 4th quarter valued at about $30,000. Stone House Investment Management LLC acquired a new stake in Medpace in the third quarter valued at approximately $33,000. Ashton Thomas Securities LLC acquired a new stake in Medpace in the third quarter valued at approximately $37,000. Capital Performance Advisors LLP acquired a new stake in Medpace in the third quarter valued at approximately $46,000. Finally, True Wealth Design LLC raised its holdings in Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after acquiring an additional 168 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of Medpace stock opened at $342.41 on Friday. The stock has a market capitalization of $10.64 billion, a price-to-earnings ratio of 29.98, a PEG ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The firm’s fifty day simple moving average is $343.70 and its 200-day simple moving average is $348.88.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Analysts anticipate that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MEDP shares. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. TD Cowen cut their price target on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.